Top in cardiology: Heart attacks spike after cold spells; Wegovy linked to CV benefits
Click Here to Manage Email Alerts
Hospitalizations for heart attack increased after cold spells in Sweden, researchers reported at the European Society of Cardiology Congress.
After an initial delay, the increase in hospitalizations occurred 2 to 6 days after individuals experienced exposure to the cold weather.
“There is interest in weather episodes, with hot temperature and its relationship to [cardiovascular] death. Here, we see in a certain part of northern Europe that cold spells also may affect [cardiovascular] risk,” Stefan Agewall, MD, PhD, senior cardiology professor at Oslo University in Norway, told Healio.
It was the top story in cardiology last week.
In another top story, a post hoc analysis of the SELECT trial revealed a link between semaglutide (Wegovy, Novo Nordisk) and significant reductions in cardiovascular events regardless of sex.
Read these and more top stories in cardiology below:
Cold weather exposure may increase risk for heart attack
Hospital admissions for heart attack increased after exposure to lower air temperature and cold spells, researchers reported at the European Society of Cardiology Congress. Read more.
Wegovy shows CV benefits among SELECT participants regardless of sex
Women with obesity and atherosclerotic cardiovascular disease without diabetes experience fewer cardiovascular events vs. men enrolled in the SELECT trial; however, semaglutide was linked to significant reductions in cardiovascular events regardless of sex, a speaker at European Society of Cardiology Congress reported. Read more.
Early pregnancy heart health important in preventing gestational hypertension
Optimal heart health during the first trimester of pregnancy was associated with lower risk for hypertensive disorders of pregnancy, according to a speaker at the Hypertension Scientific Sessions. Read more.
SGLT2s could prevent cardiotoxic effects of cancer therapies in patients with diabetes
SGLT2 inhibition may prevent cancer therapy-related cardiac dysfunction and improve other outcomes in patients with diabetes undergoing cancer therapy, researchers reported. Read more.
ALXN2220 for ATTR amyloidosis with cardiomyopathy granted fast track designation
AstraZeneca announced its rare disease unit, Alexion, has been granted fast track designation by the FDA for ALXN2220 for the treatment of transthyretin amyloidosis with cardiomyopathy. Read more.